ICMR and Zydus Lifesciences initiate second phase proof-of-concept trial for Desidustat in patients with sickle cell disease

Desidustat has been discovered at Zydus Lifesciences’s R&D labs, and was recently approved for treatment of anaemia in chronic kidney disease patients